Aptose Biosciences Inc. (APTO)
NASDAQ: APTO · Real-Time Price · USD
1.710
-1.455 (-45.97%)
At close: Apr 1, 2025, 4:00 PM
1.680
-0.030 (-1.75%)
After-hours: Apr 1, 2025, 4:51 PM EDT
Aptose Biosciences Employees
As of December 31, 2023, Aptose Biosciences had 36 total employees, including 35 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
36
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$706,389
Market Cap
6.99M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
APTO News
- 4 days ago - Aptose Reports Year End 2024 Results and Corporate Highlights - GlobeNewsWire
- 15 days ago - Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance - GlobeNewsWire
- 5 weeks ago - Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday? - Benzinga
- 5 weeks ago - Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort - GlobeNewsWire
- 5 weeks ago - Aptose Announces Reverse Share Split - GlobeNewsWire
- 6 weeks ago - Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility - GlobeNewsWire
- 6 weeks ago - Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial - GlobeNewsWire
- 2 months ago - Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial - GlobeNewsWire